PCA
ACAD icon

Pallas Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Pallas Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Sell
11,584
-707
-6% -$15.6K 0.01% 743
2026
Q1 		$274K Sell
12,291
-901
-7% -$21.5K 0.01% 663
2025
Q4 		$352K Buy
13,192
+512
+4% +$12.2K 0.01% 639
2025
Q3 		$271K Buy
12,680
+16
+0.1% +$378 0.01% 702
2025
Q2 		$273K Buy
+12,664
New +$235K 0.01% 682

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pallas Capital Advisors's ACAD Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 5.8% in Q2 2026, selling an estimated $15.6K and leaving 11,584 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #743.

Pallas Capital Advisors first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. The position peaked at $352K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Pallas Capital Advisors held 11,584 shares of Acadia Pharmaceuticals worth $293K as of Q2 2026.
  • Pallas Capital Advisors sold 707 Acadia Pharmaceuticals shares in Q2 2026, an estimated $15.6K.
  • Acadia Pharmaceuticals made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #743 holding.
  • Pallas Capital Advisors first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Pallas Capital Advisors's Acadia Pharmaceuticals position peaked at $352K in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.